viagenpumatucel-l
Vaccineexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01504542)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3137340 ↗
Also known as
- hs-110
- hs110 vaccine
- viagenpumatucel-l
- viagenpumatucel-l
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04116710 | Phase 1 | Nov 30, 2019 | Heat Biologics, Providence Cancer Institute |
| NCT02439450 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2015 | Heat Biologics, Washington University in St. Louis |
| NCT02117024 | Phase 2 | Jul 1, 2014 | Heat Biologics, University of Pennsylvania |
| NCT01504542 | Phase 2 | Dec 1, 2011 | Heat Biologics, Mary Crowley Cancer Center |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Heat Biologics | For profit | 4 | 4 | 2 | 2011 |
| Mary Crowley Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Providence Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2019 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Washington University in St. Louis | Academic/Hospital | 1 | 0 | 1 | 2015 |
5 organizations
Page 1 / 1